Data from a pair of placebo-controlled Phase I trials in 58 healthy volunteers total showed that single and multiple ascending-doses of once-daily ARI-3037MO for 14 days were well tolerated with no treatment-related adverse events reported....

This month, Arisaph will begin a placebo-controlled, dose-escalation Phase I trial to evaluate a single dose of once-daily ARI-3037MO in about 40 healthy volunteers. Arisaph said it plans to start a multiple ascending-dose Phase Ib...